

Harris 09/285,292

03/05/2006

=> d ibib abs ind l6 l-1

L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:725793 HCAPLUS
DOCUMENT NUMBER: 133:291918
TITLE: CYP24 gene amplification and its use as marker for
presence or progression of or predisposition to cancer
INVENTOR(S): Albertson, Donna G.; Pinkel, Daniel
; Collins, Colin; Gray, Joe W.;
Ystra, Bauke
PATENT ASSIGNEE(S): Regents of the University of California, USA
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000060109	A1	20001012	WO 2000-US5972	20000306
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2367291	AA	20001012	CA 2000-2367291	20000306
EP 1255850	A1	20021113	EP 2000-916145	20000306
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
PRIORITY APPLN. INFO.:			US 1999-285292	A 19990402
			WO 2000-US5972	W 20000306

AB This invention pertains to the discovery that an amplification of the CYP24 gene or an increase in CYP24 activity is a marker for the presence of, progression of, or predisposition to, a cancer (e.g., breast cancer). Using this information, this invention provides methods of detecting a predisposition to cancer in an animal. The methods involve (i) providing a biol. sample from an animal (e.g. a human patient); (ii) detecting the level of CYP24 within the biol. sample; and (iii) comparing the level of CYP24 with a level of CYP24 in a control sample taken from a normal, cancer-free tissue where an increased level of CYP24 in the biol. sample compared to the level of CYP24 in the control sample indicates the presence of said cancer in said animal.

IC ICM C12Q001-00
ICS C12Q001-02; C12Q001-24; C12Q001-25; C12N009-00; C12N005-00;
C12N005-06; C12N005-08; G01N001-00; G01N001-10; G01N031-00;
G01N033-48; G01N033-483; G01N033-487; G01N033-49; G01N033-493;
G01N031-10

CC 3-1 (Biochemical Genetics)

Section cross-reference(s): 14

ST CYP24 gene amplification cancer diagnosis prognosis

IT Animal

Blood analysis

Cat (Felis catus)

Cattle

Cerebrospinal fluid

Dog (Canis familiaris)

Horse (Equus caballus)

Immunotherapy

Lagomorpha

Mammal (Mammalia)

Mouse

Primate
 Radiotherapy
 Surgery
 Swine
 Urine analysis
 (CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
 IT Gene, animal
 mRNA
 RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)
 (CYP24; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
 IT Gene, animal
 RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)
 (VDR, as reference; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
 IT Recombination, genetic
 (amplification; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
 IT Antitumor agents
 (anti-CYP24; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
 IT Antisense oligonucleotides
 Ribozymes
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (anti-CYP24; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
 IT Therapy
 (antihormone; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
 IT Biotechnology
 (biochips, comparative genomic hybridization on; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
 IT Antitumor agents
 Antitumor agents
 (brain, CYP24 inhibitors; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
 IT Cheek
 (buccal scrape; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
 IT Chemotherapy
 Diagnosis
 (cancer; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
 IT Antitumor agents
 (colorectal, CYP24 inhibitors; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
 IT Intestine, neoplasm
 Intestine, neoplasm
 (colorectal, inhibitors, CYP24 inhibitors; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
 IT Nucleic acid hybridization
 (comparative genomic hybridization; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to

cancer)
IT Neoplasm
(diagnosis; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
IT Vitamin D receptors
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)
(gene VDR, as reference; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
IT Brain, neoplasm
Brain, neoplasm
Lung, neoplasm
Lung, neoplasm
Ovary, neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Pancreas, neoplasm
(inhibitors, CYP24 inhibitors; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
IT Antitumor agents
(leukemia, CYP24 inhibitors; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
IT Antitumor agents
Antitumor agents
(lung, CYP24 inhibitors; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
IT Antitumor agents
(lymphoma, CYP24 inhibitors; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
IT Antitumor agents
(mammary gland, CYP24 inhibitors; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
IT Antitumor agents
(metastasis, CYP24 inhibitors; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
IT Mammary gland
Mammary gland
Prostate gland
Prostate gland
(neoplasm, inhibitors, CYP24 inhibitors; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
IT Antitumor agents
Antitumor agents
(ovary, CYP24 inhibitors; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
IT Antitumor agents
Antitumor agents
(pancreas, CYP24 inhibitors; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
IT Antitumor agents
(prostate gland, CYP24 inhibitors; CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)
IT 53112-53-1, 25-Hydroxyvitamin D3 24-hydroxylase
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence)
(CYP24 gene amplification and its use as marker for presence or progression of or predisposition to cancer)

IT 300884-86-0, 1: PN: WO0060109 TABLE: 1 unclaimed DNA 300884-87-1, 2: PN:
WO0060109 TABLE: 1 unclaimed DNA 300884-88-2, 3: PN: WO0060109 TABLE: 1
unclaimed DNA 300884-89-3, 4: PN: WO0060109 TABLE: 1 unclaimed DNA
300884-90-6, 5: PN: WO0060109 TABLE: 1 unclaimed DNA 300884-91-7, 6: PN:
WO0060109 TABLE: 1 unclaimed DNA

RL: PRP (Properties)

(unclaimed nucleotide sequence; cYP24 gene amplification and its use as
marker for presence or progression of or predisposition to cancer)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT